{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:43:56Z","timestamp":1761975836760,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10557-020-07036-3","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T08:08:43Z","timestamp":1594282123000},"page":"755-762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of the Effect of Sacubitril\/Valsartan on Left Ventricular Systolic Function in Patients with Non-ischaemic and Ischaemic Cardiomyopathy"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5017-8657","authenticated-orcid":false,"given":"Adam","family":"Ioannou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Metaxa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steny","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit K. J.","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos G.","family":"Missouris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"7036_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijcard.2013.12.028","volume":"171","author":"C Cook","year":"2014","unstructured":"Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171:368\u201376.","journal-title":"Int J Cardiol"},{"key":"7036_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293\u2013302.","journal-title":"N Engl J Med"},{"key":"7036_CR3","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","unstructured":"The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429\u201335.","journal-title":"N Engl J Med"},{"key":"7036_CR4","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","volume":"344","author":"M Packer","year":"2001","unstructured":"Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651\u20138.","journal-title":"N Engl J Med"},{"key":"7036_CR5","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"MERIT-HF Study Group","year":"1999","unstructured":"MERIT-HF Study Group. Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001\u20137.","journal-title":"Lancet."},{"doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709\u2013717.","key":"7036_CR6","DOI":"10.1056\/NEJM199909023411001"},{"key":"7036_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1161\/01.HYP.0000146483.78994.56","volume":"44","author":"NL Cruden","year":"2004","unstructured":"Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension. 2004;44:913\u20138.","journal-title":"Hypertension."},{"key":"7036_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1042\/cs0910283","volume":"91","author":"MT Rademaker","year":"1996","unstructured":"Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci (Lond). 1996;91:283\u201391.","journal-title":"Clin Sci (Lond)"},{"key":"7036_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000092457","volume":"103","author":"C Maric","year":"2006","unstructured":"Maric C, Zheng W, Walther T. Interactions between angiotensin ll and atrial natriuretic peptide in renomedullary interstitial cells: the role of neutral endopeptidase. Nephron Physiol. 2006;103:149\u201356.","journal-title":"Nephron Physiol"},{"doi-asserted-by":"crossref","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371(11):993\u20131004.","key":"7036_CR10","DOI":"10.1056\/NEJMoa1409077"},{"doi-asserted-by":"crossref","unstructured":"Lang RM, Bierig M, Devereux RB, et al; Chamber Quantification Writing Group; American Society of Echocardiography\u2019s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440\u20131463.","key":"7036_CR11","DOI":"10.1016\/j.echo.2005.10.005"},{"unstructured":"Douglas PS, Khandheria B, Stainback RF, et al; American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group; American Society of Echocardiography; American College of Emergency Physicians; American Society of Nuclear Cardiology; Society for Cardiovascular Angiography and Interventions; Society of Cardiovascular Computed Tomography; Society for Cardiovascular Magnetic Resonance; American College of Chest Physicians; Society of Critical Care Medicine. ACCF\/ASE\/ACEP\/ASNC\/SCAI\/SCCT\/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Coll Cardiol. 2007;50:187\u2013204.","key":"7036_CR12"},{"key":"7036_CR13","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1161\/01.CIR.64.4.744","volume":"64","author":"MA Quinones","year":"1981","unstructured":"Quinones MA, Waggoner AD, Reduto LA, Nelson JG, Young JB, Winters WL Jr, et al. A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation. 1981;64:744\u201353.","journal-title":"Circulation."},{"key":"7036_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0735-1097(97)00144-7","volume":"30","author":"RA Nishimura","year":"1997","unstructured":"Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography in the clinician\u2019s Rosetta stone. J Am Coll Cardiol. 1997;30:8\u201318.","journal-title":"J Am Coll Cardiol"},{"key":"7036_CR15","first-page":"108","volume":"7","author":"A Almufleh","year":"2017","unstructured":"Almufleh A, Marbach J, Chih S, Stadnick E, Davies R, Liu P, et al. Ejection fraction improvement and reverse remodeling achieved with sacubitril\/valsartan in heart failure with reduced ejection fraction patients. Am J Cardiovasc Dis. 2017;7:108\u201313.","journal-title":"Am J Cardiovasc Dis"},{"key":"7036_CR16","first-page":"100418","volume":"25","author":"G Bayard","year":"2019","unstructured":"Bayard G, Da Costa A, Pierrard R, Rom\u00e9yer-Bouchard C, Guichard JB, Isaaz K. Impact of sacubitril\/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation. Int J Cardiol Heart Vasc. 2019;25:100418.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"7036_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.yjmcc.2017.06.003","volume":"108","author":"Y Xia","year":"2017","unstructured":"Xia Y, Chen Z, Chen A, Fu M, Dong Z, Hu K, et al. LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell Cardiol. 2017;108:138\u201348.","journal-title":"J Mol Cell Cardiol"},{"key":"7036_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1751-7133.2011.00255.x","volume":"17","author":"L Chen","year":"2011","unstructured":"Chen L, Knowlton AA. Mitochondrial dynamics in heart failure. Congest Heart Fail. 2011;17:257\u201361.","journal-title":"Congest Heart Fail"},{"key":"7036_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/cvr\/cvq237","volume":"88","author":"SB Ong","year":"2010","unstructured":"Ong SB, Hausenloy DJ. Mitochondrial morphology and cardiovascular disease. Cardiovasc Res. 2010;88:16\u201329.","journal-title":"Cardiovasc Res"},{"key":"7036_CR20","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1091\/mbc.e04-04-0294","volume":"15","author":"YJ Lee","year":"2004","unstructured":"Lee YJ, Jeong SY, Karbowski M, Smith CL, Youle RJ. Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. Mol Biol Cell. 2004;15:5001\u201311.","journal-title":"Mol Biol Cell"},{"key":"7036_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10741-012-9330-2","volume":"18","author":"J Mar\u00edn-Garc\u00eda","year":"2013","unstructured":"Mar\u00edn-Garc\u00eda J, Akhmedov AT, Moe GW. Mitochondria in heart failure: the emerging role of mitochondrial dynamics. Heart Fail Rev. 2013;18:439\u201356.","journal-title":"Heart Fail Rev"},{"key":"7036_CR22","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1161\/01.CIR.84.3.1024","volume":"84","author":"MR Bristow","year":"1991","unstructured":"Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, et al. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:1024\u201339.","journal-title":"Circulation."},{"key":"7036_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ahj.2007.05.013","volume":"154","author":"P de Groote","year":"2007","unstructured":"de Groote P, Delour P, Mouquet F, Lamblin N, Dagorn J, Hennebert O, et al. The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. Am Heart J. 2007;154:589\u201395.","journal-title":"Am Heart J"},{"key":"7036_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/CIRCHEARTFAILURE.108.806240","volume":"2","author":"MS Maurer","year":"2009","unstructured":"Maurer MS, Sackner-Bernstein JD, El-Khoury Rumbarger L, Yushak M, King DL, Burkhoff D. Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure. Circ Heart Fail. 2009;2:189\u201396.","journal-title":"Circ Heart Fail"},{"key":"7036_CR25","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/01.CIR.0000095029.57483.60","volume":"108","author":"D Bello","year":"2003","unstructured":"Bello D, Shah DJ, Farah GM, Di Luzio S, Parker M, Johnson MR, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation. 2003;108:1945\u201353.","journal-title":"Circulation."},{"issue":"6","key":"7036_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011077","volume":"8","author":"CS Park","year":"2019","unstructured":"Park CS, Park JJ, Mebazaa A, Oh IY, Park HA, Cho HJ, et al. Characteristics, outcomes, and treatment of heart failure with improved ejection fraction. J Am Heart Assoc. 2019;8(6):e011077.","journal-title":"J Am Heart Assoc"},{"key":"7036_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jchf.2019.02.015","volume":"7","author":"C Balmforth","year":"2019","unstructured":"Balmforth C, Simpson J, Shen L, Jhund PS, Lefkowitz M, Rizkala AR, et al. Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC Heart Fail. 2019;7:457\u201365.","journal-title":"JACC Heart Fail"},{"key":"7036_CR28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"7036_CR29","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","volume":"36","author":"PS Jhund","year":"2015","unstructured":"Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, et al. PARADIGM-HF Investigators and Committees. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36:2576\u201384.","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07036-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-07036-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-07036-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:12:59Z","timestamp":1625789579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-07036-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7036"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-07036-3","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"5 July 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The survey was approved by our Trust Audit Department with reference CB671.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of Ethics Committee Approval"}},{"value":"As a survey report using clinically collected, non-identifiable data, this work does not fall under the remit of the National Health Service Research Ethics Committees.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}